Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more
Innoviva Inc (INVA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.046x
Based on the latest financial reports, Innoviva Inc (INVA) has a cash flow conversion efficiency ratio of 0.046x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($54.51 Million) by net assets ($1.17 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Innoviva Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Innoviva Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Innoviva Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innoviva Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Co-Tech Development
TWO:8358
|
0.000x |
|
ISA ENERGIA BRASIL
SA:ISAE3
|
-0.028x |
|
Landis+Gyr Group AG
OTCGREY:LGYRF
|
-0.031x |
|
Zhongrun Resources Investment
SHE:000506
|
0.089x |
|
CSPC Innovation Pharmaceutical Co Ltd Class A
SHE:300765
|
-0.237x |
|
XiaMen HongXin Electron-tech Co Ltd
SHE:300657
|
-0.095x |
|
Veris Residential Inc
NYSE:VRE
|
0.011x |
|
Transcend Information Inc
TW:2451
|
0.123x |
Annual Cash Flow Conversion Efficiency for Innoviva Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Innoviva Inc from 2002 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.17 Billion | $196.93 Million | 0.168x | -38.50% |
| 2024-12-31 | $691.16 Million | $188.69 Million | 0.273x | +30.63% |
| 2023-12-31 | $674.96 Million | $141.06 Million | 0.209x | -41.38% |
| 2022-12-31 | $565.79 Million | $201.73 Million | 0.357x | -48.46% |
| 2021-12-31 | $525.93 Million | $363.81 Million | 0.692x | +34.29% |
| 2020-12-31 | $607.84 Million | $313.11 Million | 0.515x | -31.55% |
| 2019-12-31 | $342.12 Million | $257.46 Million | 0.753x | -46.45% |
| 2018-12-31 | $159.05 Million | $223.53 Million | 1.405x | +340.64% |
| 2017-12-31 | $-242.71 Million | $141.75 Million | -0.584x | -238.05% |
| 2016-12-31 | $-352.99 Million | $60.98 Million | -0.173x | -484.31% |
| 2015-12-31 | $-342.64 Million | $10.13 Million | -0.030x | -105.05% |
| 2014-12-31 | $-223.35 Million | $-130.72 Million | 0.585x | +235.08% |
| 2013-12-31 | $299.12 Million | $-129.60 Million | -0.433x | +47.50% |
| 2012-12-31 | $155.03 Million | $-127.95 Million | -0.825x | -181.33% |
| 2011-12-31 | $-87.05 Million | $-88.34 Million | 1.015x | -69.72% |
| 2010-12-31 | $-22.42 Million | $-75.14 Million | 3.352x | +990.94% |
| 2009-12-31 | $-188.99 Million | $-58.06 Million | 0.307x | -58.50% |
| 2008-12-31 | $-134.95 Million | $-99.91 Million | 0.740x | -53.00% |
| 2007-12-31 | $-66.26 Million | $-104.37 Million | 1.575x | +195.16% |
| 2006-12-31 | $63.31 Million | $-104.79 Million | -1.655x | -68.17% |
| 2005-12-31 | $59.58 Million | $-58.65 Million | -0.984x | -291.79% |
| 2004-12-31 | $190.37 Million | $-47.82 Million | -0.251x | -337.58% |
| 2003-12-31 | $-299.57 Million | $-31.68 Million | 0.106x | -58.15% |
| 2002-12-31 | $-231.93 Million | $-58.60 Million | 0.253x | -- |